Answers are grounded in this paper and cite their sources.
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has killed more than one million lives and infected almost 40 million people around the world In the absence of approved antiviral drugs and vaccines for COVID-19, drug repurposing could be an effective strategy to fast forward COVID-19 drug discovery process In this study, we screened 160 potential drugs from Therapeutic Target Database against 13 protein targets (12 SARS-CoV-2 proteins and 1 human protein) using an inverse docking approach Our preliminary result showed that suramin, a poly-sulfonated compound used to treat sleeping sickness, came out with the strongest binding affinity against 3 protein targets (Spike protein, Nucleocapsid protein, ACE2) Suramin formed the strongest complexes with spike protein (prefusion) and nucleocapsid protein (binding affinity:-11 2 Kcal/mol, each) from SARS-CoV-2 The best candidate was also evaluated through molecular dynamics simulation It is clearly confirmed that this active compound has stable binding during 10 ns simulation We concluded that drug repurposing based on virtual screening technique revealed that Suramin is the most potential to bind nucleocapsid and Spike protein of SARS-CoV-2 ACE2 is also considered as a new target of Suramin
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: